American Heart Journal
Volume 156, Issue 1 , Pages 112-119, July 2008

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004

  • Heli Ghandehari, BS

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA
  • ,
  • Sachin Kamal-Bahl, PhD

      Affiliations

    • Global Outcomes Research, Merck & Co., Inc., West Point, PA
  • ,
  • Nathan D. Wong, PhD, MPH

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA
    • Corresponding Author InformationReprint requests: Nathan D. Wong, PhD, Heart Disease Prevention Program, C240 Medical Sciences, University of California, Irvine, CA 92697.

Received 18 October 2007; accepted 4 March 2008. published online 16 May 2008.

Background

Despite improvements in low-density lipoprotein cholesterol (LDL-C) levels, recent national data are limited regarding the proportion of adults at recommended lipid levels according to the presence of cardiovascular disease (CVD) and related comorbidities. We evaluated the proportion of US adults with and without these conditions at (and distance to) recommended levels of LDL-C, non–high-density lipoprotein cholesterol (non–HDL-C), HDL-C, and triglycerides.

Methods

We analyzed data from adults aged ≥20 who had fasted for 8 or more hours (n = 2,883, weighted to a US population of 128.5 million) in the National Health and Nutrition Examination Survey 2003-2004, a nationally representative cross-sectional survey. The number of adults at National Cholesterol Education Program recommended levels for LDL-C, non–HDL-C, HDL-C, triglycerides, and combined lipids, stratified by sex, age group, ethnicity, and the presence of CVD comorbidities was determined.

Results

Although 85% to 89% of persons without CVD or related comorbidities were at recommended levels for LDL-C, non–HDL-C, HDL-C, and triglycerides, only 36% to 37% of those with CVD or related comorbidities were at recommended levels for LDL-C and non–HDL-C, and only 17% were at recommended levels for all lipids. Treated persons compared with those untreated had significantly lower LDL-C (112.3 vs 156.7 mg/dL, P < .001) and non–HDL-C levels (145.9 vs 188.7 mg/dL, P < .001), but similar HDL-C (52.0 vs 50.1 mg/dL, P = .09) and triglyceride (160.1 vs 148.7 mg/dL, P = .20) levels.

Conclusions

Despite improved LDL-C levels, many adults, especially with CVD or related comorbidities, are not at recommended levels for all lipids. Improved treatment efforts to target the spectrum of dyslipidemia are needed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Presented in part at the American Heart Association Scientific Sessions, Orlando, FL, November 2007. This study was supported by a contract from Merck & Co., Inc., to the University of California, Irvine.

PII: S0002-8703(08)00165-8

doi:10.1016/j.ahj.2008.03.005

American Heart Journal
Volume 156, Issue 1 , Pages 112-119, July 2008